1 Adaptive immunity to human coronaviruses is widespread but low in magnitude

- 2
- 3 Hyon-Xhi Tan^{1*}, Wen Shi Lee^{1*}, Kathleen M Wragg¹, Christina Nelson¹, Robyn Esterbauer¹,
- 4 Hannah G Kelly^{1,2}, Thakshila Amarasena¹, Robert Jones³, Graham Starkey³, Bao Zhong Wang³,
- 5 Osamu Yoshino³, Thomas Tiang³, M Lindsay Grayson⁴, Helen Opdam^{5,6}, Rohit D'Costa^{7,8},
- 6 Angela Vago³, The Austin Liver Transplant Perfusionist Group⁹, Laura K Mackay¹, Claire L
- 7 Gordon^{1,4}, Adam K Wheatley¹, Stephen J Kent^{1,2,10}, Jennifer A Juno¹
- 8
- 9 *These authors contributed equally
- 10
- ¹¹ ¹Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty
- 12 institute for Infection and Immunity, Melbourne, VIC, Australia
- 13 ²Australian Research Council Centre for Excellence in Convergent Bio-Nano Science and
- 14 Technology, University of Melbourne, Melbourne, VIC, Australia
- ³Department of Surgery, Austin Health, Heidelberg, Victoria 3084, Australia.
- ⁴Department of Infectious Diseases, Austin Health, Heidelberg, Victoria 3084, Australia.
- ¹⁷ ⁵DonateLife, The Australian Organ and Tissue Authority, ACT 2601, Australia.
- 18 ⁶Department of Intensive Care, Austin Health, Heidelberg, Victoria 3084, Australia
- 19 ⁷DonateLife Victoria, Carlton, Victoria 3053, Australia
- 20 ⁸Intensive Care Unit, The Royal Melbourne Hospital, Parkville 3050, Victoria, Australia
- 21 ⁹The Austin Liver Transplant Perfusionist Group comprises Greg Przybylowski, Darren Pritchard,
- 22 Rod Moore, Robert Balakas, Casey Asmus and Rene Batac. Austin Health Operating Suite,
- 23 Heidelberg, Victoria 3084, Australia.
- ²⁴ ¹⁰Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred 18 Hospital
- 25 and Central Clinical School, Monash University, Melbourne, VIC, Australia
- 26
- 27 Corresponding author:
- 28 Dr. Jennifer Juno
- 29 jennifer.juno@unimelb.edu.au
- 30 792 Elizabeth St, Melbourne VIC 3000

31 Abstract

32	Endemic human coronaviruses (hCoV) circulate worldwide but cause minimal mortality.
33	Although seroconversion to hCoV is near ubiquitous during childhood, little is known about
34	hCoV-specific T cell memory in adults. We quantified CD4 T cell and antibody responses to
35	hCoV spike antigens in 42 SARS-CoV-2 uninfected individuals. T cell responses were
36	widespread within conventional memory and cTFH compartments but did not correlate with IgG
37	titres. SARS-CoV-2 cross-reactive T cells were observed in 48% of participants and correlated
38	with HKU1 memory. hCoV-specific T cells exhibited a CCR6 ⁺ central memory phenotype in the
39	blood, but were enriched for frequency and CXCR3 expression in human lung draining lymph
40	nodes. Overall, hCoV-specific humoral and cellular memory are independently maintained, with
41	a shared phenotype existing among coronavirus-specific CD4 T cells. This understanding of
42	endemic coronavirus immunity provides insight into the homeostatic maintenance of immune
43	responses that are likely to be critical components of protection against SARS-CoV-2.

45 Introduction

In contrast to the high pathogenicity of MERS-CoV, SARS-CoV and SARS-CoV-2 46 47 coronaviruses, endemic human coronaviruses (hCoV) circulate worldwide but typically cause 48 common colds with only limited morbidity and mortality¹. Endemic hCoV encompass two alpha-49 coronaviruses (α CoV), NL63 and 229E, and two beta-coronaviruses (β CoV), HKU1 and OC43¹. 50 Sero-epidemiological studies suggest that infection and seroconversion to hCoV occurs during 51 early childhood (typically by 4 years of age)²⁻⁴, although there are discrepant reports on the 52 prevalence of each virus within distinct geographical cohorts^{2,5}. Despite the early development of 53 immunity against multiple hCoV, most adults remain susceptible to periodic reinfection⁶⁻⁸, with increased susceptibility among immunocompromised individuals⁹⁻¹¹. This suggests the 54 55 magnitude and/or quality of hCoV-targeted immunity in adults is insufficient for sterilizing 56 protection but instead may limit the burden of disease to asymptomatic or mild infection⁸. 57 Defining the extent of serological and/or cellular immunity required to protect individuals from 58 reinfection or severe disease remains a key question in the SARS-CoV-2 pandemic. As 59 neutralizing responses wane after CoV infection, it is likely that a combination of serum 60 antibody and B cell / T cell memory provide longer-term protection from the recurrence of 61 disease^{12,13}. The study of hCoV-specific T and B cell memory can therefore provide a key 62 preview into the development of durable, protective SARS-CoV-2 immunity. 63 Characterisation of population-level immunity to hCoV can also inform our understanding of 64 cross-reactive immune responses between high pathogenicity and endemic CoV. Studies of 65 SARS-CoV-2-specific immunity in uninfected individuals clearly demonstrate pre-existing cross-reactive antibody¹⁴⁻¹⁶, B cell¹⁶ and T cell responses¹⁷⁻²². Nevertheless, it is currently 66 67 unclear what contribution, if any, cross-reactive immunity plays in modulating the response to

68	SARS-CoV-2 infection or vaccination ²³ . Detailed analyses of cross-reactive T cells suggest the
69	majority of such responses are dominated by CD4 T cells and directed toward non-RBD epitopes
70	of the spike (S) protein ^{18,21,24} . To date, however, consensus regarding the origin of these cross-
71	reactive responses is lacking, with evidence both for ¹⁸ and against ²⁵ a major contribution from
72	hCoV-specific memory T cells.
73	Deconvolution of cross-reactive SARS-CoV-2 responses and de novo SARS-CoV-2 immunity
74	requires a more detailed understanding of hCoV-specific serological and cellular memory.
75	Relatively little is known about population-level T or B cell memory to hCoV in adults, despite
76	evidence suggesting an impact of recent hCoV infection on COVID-19 severity ²⁶ . Several
77	groups find widespread but modest CD4 T cell responses to hCoV proteins, with estimates for
78	the prevalence of memory responses ranging from 70-100% of study participants ^{24,25,27} .
79	Detection of hCoV-specific CD8 T cell responses has been less reported ²⁷ , and the prevalence of
80	cross-reactive SARS-CoV-2-specific responses in these cohorts varies substantially ^{24,25} .
81	Furthermore, data comparing hCoV-specific T or B cell responses in the circulation with the
82	presence or absence of such responses in the respiratory tract or secondary lymphoid organs
83	(SLO) is lacking. Studies in animal models suggest that respiratory infections can generate long-
84	lived T cell memory in lung draining lymph nodes (LDLN) ²⁸ , raising the possibility of analogous
85	responses following hCoV infection.
86	To address these knowledge gaps, we assessed the prevalence and phenotypic characteristics of
87	hCoV spike-specific antibody, memory T cell and memory B cell responses in a cohort of
88	SARS-CoV-2 uninfected adults. We find that the magnitude of hCoV immunity is independent
89	of age and is characterized by robust antibody titres, widespread CD4 T cell memory within both
90	Tmem and cTFH populations, and an enrichment of T cell memory in LDLN. In contrast,

- 91 neutralizing antibody activity is relatively low and memory B cells are infrequently detected in
- 92 either the circulation or LDLN. Overall, our data detail a consistent pattern of hCoV-specific
- 93 immune memory in the circulation and SLO which likely co-ordinate to provide long-term
- 94 protection from hCoV infection.

95 **Results**

- 96 hCoV-specific antibody and CD4 T cell memory is common among adults
- 97 We recruited a cohort of 42 SARS-CoV-2 uninfected adults (n=21 male, n=21 female), ranging
- 98 in age from 18-67 years with no recent cold or COVID-19 symptoms (Figure 1A). Consistent
- 99 with previous studies^{15,16}, we detected baseline plasma antibody responses to one or more hCoV
- 100 S antigens in all participants, with substantially lower reactivity toward SARS-CoV-2 S (herein
- 101 CoV-2; Figure 1B). Plasma IgG endpoint titres for hCoV antigens ranged from 1:176 to 1:18268
- 102 (median 1:1485 for HKU1, IQR 1:886.8-2045; median 1:4475 for OC43, IQR 1:2082-6979;
- 103 median 1:2066 for 229E, IQR 1:1185-3789; median 1:1716 for NL63, IQR 1:1193-2731).

- 105 To determine the distribution of CD4 T cell memory responses, we stimulated PBMC with
- 106 recombinant S antigens and quantified antigen-specific Tmem (CD3⁺CD4⁺CD45RA⁺CXCR5⁻)
- 107 by measuring upregulation of the activation markers CD25 and OX-40 by flow cytometry (a
- 108 well-established activation-induced marker (AIM) assay²⁹⁻³¹) (Figure 1C; gating in Supplemental
- 109 Figure 1). Across the cohort, 88% of individuals exhibited a memory response greater than
- 110 0.01% above background³² to any hCoV S antigen (Figure 1D). Interestingly, the prevalence of
- responses was highest to HKU1 S (86% of participants), and lowest to NL63, with only 50% of
- 112 individuals exhibiting NL63 S-specific responses (Figure 1D). The magnitude of responses to
- 113 hCoV S antigens ranged from undetectable to a maximum of 0.84% of the Tmem compartment
- 114 (Figure 1E). Among individuals with above-background responses, median antigen-specific
- 115 Tmem frequencies were highest to HKU1 (median 0.133%, IQR 0.056-0.248, n=36), followed
- 116 by OC43 (median 0.106%, IQR 0.049-0.170, n=34), NL63 (median 0.093%, IQR 0.055-0.168,
- 117 n=21), and 229E (median 0.080%, IQR 0.050-0.124, n=27). Similar to other cohorts^{17,19}, we find

118	48% of participants (n=20) demonstrated cross-reactive response to CoV-2 S with a median
119	frequency of 0.049% (IQR 0.027-0.160), despite no evidence of prior infection (Figure 1D/E). T
120	cell responses were similar when measured using either CD25/OX-40 or CD137/OX-40 ¹⁹ AIM
121	assays (Supplementary Figure 2A-C). Across the cohort, there was no relationship between the
122	total frequency of hCoV S-specific Tmem and age, or any association with gender
123	(Supplementary Figure 3A-B).
124	
125	$hCoV$ -specific CD4 Tmem are predominately T_{CM} cells with a CCR6 ⁺ phenotype
126	Given divergent host receptor specificity and possible differences in tissue tropism among
127	hCoV ¹ , we assessed whether memory or chemokine receptor phenotypes differed among S-
128	specific CD4 T cell populations (gating in Supplementary Figure 1B). Similar to the parental
129	Tmem population, hCoV S-specific and CoV-2 cross-reactive CD4 T cells were predominately
130	CD27 ⁺ CCR7 ⁺ , classically defined as central memory T cells (T _{CM} ; Figure 2A-B). In contrast to
131	the bulk Tmem population, however, hCoV S-specific cells were substantially enriched for
132	CCR6 expression (with or without co-expression of CXCR3; Figure 2C-D). When comparing
133	intra-individual responses, hCoV S-specific Tmem phenotypes were generally similar across all
134	S antigens (Figure 2E). Prior studies have also described a dominant CCR6 phenotype of CoV-2
135	S-specific Tmem among convalescent COVID-19 subjects ³³ , and here we find that CoV-2 cross-
136	reactive responses are similarly highly CCR6 biased (Figure 2D-E).
137	
138	hCoV reactivity is detected among circulating T follicular helper cell (TFH) memory

139 Circulating TFH cells (cTFH; CXCR5⁺CD45RA⁻) comprise a clonally³⁴ and functionally^{29,35}

140 distinct memory CD4 T cell population identified by CXCR5 expression. Activated cTFH

141	correlate with antibody responses to infection or vaccination, and are thought to be surrogates of
142	germinal centre (GC) TFH activity ^{36,37} . Resting cTFH, in contrast, may represent a long-lived,
143	homeostatic memory population from which recall responses can be elicited even years after
144	antigen exposure ³⁸⁻⁴¹ . Like conventional Tmem, hCoV-specific and cross-reactive cTFH
145	responses were widely detected across the cohort (Figure 3A). The frequency of donors
146	exhibiting cTFH responses above 0.01% to each antigen was similar to that observed for Tmem
147	responses (90% for HKU1, 88% for OC43, 69% for 229E, 59% for NL63, 43% for CoV-2).
148	Median frequencies among responding donors were highest to HKU1 (median 0.241%, IQR
149	0.147-0.531), followed by OC43 (median 0.213%, IQR 0.126-0.424), 229E (median 0.126%,
150	IQR 0.061-0.340), NL63 (median 0.096%, IQR 0.050-0.210) and CoV-2 (median 0.085%, IQR
151	0.050-0.195) (Figure 3A).
152	Interestingly, hCoV responses comprised a greater proportion of the cTFH population compared
153	to the Tmem compartment in a paired analysis (p<0.002 for all hCoV antigens), with some
154	donors exhibiting a greater than 9-fold enrichment of hCoV-specific cells in the cTFH gate (data
155	for HKU1 shown in Figure 3B). Similar to Tmem, antigen-specific cTFH were highly enriched
156	for a CCR6 ⁺ CXCR3 ⁻ phenotype (Figure 3C-D). The phenotypes of HKU1- and CoV-2-specific
157	cTFH in SARS-CoV-2-uninfected donors are consistent with phenotypes previously described in
158	COVID-19 convalescent subjects ²⁹ . Comparison of antigen-specific cTFH and Tmem cells
159	revealed a significant enrichment of the CCR6 ⁺ CXCR3 ⁻ phenotype among cTFH, including the
160	CoV-2 cross-reactive population (Figure 3E-F). These data suggest that while hCoV memory is
161	broadly observed among both Tmem and cTFH subsets, the frequency and phenotype of these
162	responses are, to a degree, subset-specific.

164 CoV-2 cross-reactive T cells correlate with HKU1 T cell memory

165	It is currently unclear whether CoV-2 cross-reactive T cell responses arise primarily from hCoV
166	memory or reflect cross-reactivity from a broad array of antigen specificities ^{18,25} . Among the
167	cohort, subjects with CoV-2 cross-reactive CD4 T cell responses frequently exhibited memory
168	responses to multiple hCoVs (Figure 4A). We assessed the relationship between the frequency of
169	CoV-2 and hCoV memory responses and found significant correlations only between β CoV and
170	CoV-2 cross-reactivity (p=0.006 for HKU1, p=0.018 for OC43; Figure 4B). This association is
171	consistent with a greater sequence homology among β CoV strains (CoV-2, HKU1 and OC43)
172	compared to the α CoV 229E and NL63 ⁴² . ⁴² Among the subset of donors with cross-reactive
173	responses, only HKU1 memory correlated with CoV-2 cross-reactivity (p=0.030, Figure 4B).
174	Interestingly, while almost all individuals with CoV-2 cross-reactive responses exhibited HKU1
175	and OC43 memory, the converse was not observed. Indeed, individuals with relatively similar
176	patterns of hCoV reactivity could exhibit notably different CoV-2 reactivity (Figure 4C). There
177	was no significant association of demographic characteristics among individuals with or without
178	CoV-2 cross-reactive responses, although the cross-reactive group did exhibit a greater
179	representation of women compared to those without cross-reactivity (p=0.06, Supplemental
180	Figure 3C-D). Given the association between HKU1 and CoV-2 T cell frequencies, we assessed
181	whether a particular phenotype of HKU-specific Tmem was related to the presence or absence of
182	cross-reactive responses, but found no such distinctions (Supplemental Figure 3E).
183	
184	Cellular and humoral immune memory to hCoV are maintained independently
185	Studies of convalescent COVID-19 cohorts have demonstrated a strong correlation between

186 SARS-CoV-2-specific cTFH, memory B cells, binding IgG and serum neutralization^{19,29,32}, as

187 expected from a coordinated acute immune response. To assess whether such associations are 188 maintained in long-term hCoV immunity, we explored correlations between antibody and T cell responses across the cohort. Surprisingly, there was no relationship for any antigen between 189 190 plasma IgG endpoint titre and the frequency of either S-specific CD4 Tmem or cTFH (p>0.05 for 191 all; data for HKU1 and NL63 shown in Figure 5A). To gain greater insight into the coordination 192 of cellular and humoral hCoV memory, we undertook an in-depth interrogation of immunity to 193 NL63, which shares use of the cellular entry receptor ACE2 with SARS-CoV and CoV-2, and 194 therefore likely has similar tissue tropisms in vivo. 195 To assess S-specific MBC and quantify plasma neutralising activity, NL63 S-specific memory B 196 cell (MBC) probes were generated as described previously²⁹, and a novel NL63 pseudovirus-197 based neutralization assay was performed with 293T cells stably expressing hACE2 as targets. 198 MBC specific for NL63 and CoV-2 S were detected infrequently among the cohort, particularly 199 in comparison to the frequency of CoV-2 S-specific MBC previously reported among COVID-19 200 convalescent donors²⁹ (Figure 5B). Accordingly, the frequency of NL63 S-specific MBC did not 201 correlate with plasma NL63 binding IgG titres (Figure 5C). Plasma neutralising activity against 202 NL63 pseudovirus was detected among all donors tested, with a median IC₅₀ of 100.7 (n=12, 203 IQR 56.6-234.6). Neutralising activity strongly correlated with NL63 S-specific antibody titres 204 (p=0.006) but was not associated with NL63 S-specific MBC frequencies (Figure 5D). We did, 205 however, observe a trend toward a positive correlation of neutralization with NL63 S-specific 206 cTFH responses (p=0.081; Figure 5E). Given our prior observation that CCR6⁺ CoV-2 S-207 specific cTFH responses were inversely associated with neutralizing antibodies after COVID-208 19²⁹, we assessed the correlation between NL63 neutralising activity and NL63 S-specific cTFH 209 phenotype (for donors with NL63 S-specific cTFH responses, n=7). Interestingly, the frequency

- of CCR6⁺ cTFH again negatively correlated with plasma neutralization activity (p=0.048; Figure
 5E), although the small sample size is a caveat of this analysis.
- 212

213 Enrichment of HKU1 and NL63 S-specific T cells in lung-draining lymph nodes

214 Although assessment of hCoV immunity has been primarily limited to peripheral blood, studies

- suggest that repeated infections with respiratory viruses can seed long-lived memory T cell
- responses in lung and lung-draining lymph nodes (LDLN)^{28,43}.^{28,43} We therefore assessed the
- 217 frequency of HKU1, NL63 and CoV-2 S-specific CD4 T cell responses in matched LDLN (n=5)
- and lung samples (n=6) from a human tissue biobank (gating in Supplementary Figure 5). We
- 219 detected robust HKU1 and NL63 responses within the CD45RA⁻ CD4 T cell population of

220 LDLN (Figure 6A). Given the higher levels of background T cell activation in SLO compared to

- 221 peripheral blood, we validated the specificity of the hCoV responses by confirming that antigen
- stimulation also drove expression of CD154 on OX-40⁺ cells (Figure 6A). Among the 5 donors
- studied, the median frequency of HKU1 and NL63 S-specific Tmem was 1.2% (range 0.12-2.19)

and 1.12% (range 0.31-4.04), respectively (Figure 6B). Reactivity to CoV-2 S was substantially

- lower, with a median of 0.07% (range 0.01-0.99). Similar antigen-specific responses were
- 226 observed within the CD4⁺CD45RA⁻CXCR5⁺ population (Figure 6B). There was limited to no
- 227 evidence of ongoing hCoV S-specific GC TFH activity among the samples (data not shown).
- In contrast to the high frequencies of hCoV-specific CD4 T cells in LDLN, we found only
- 229 modest hCoV reactivity among lung-derived CD4 T cells (Supplementary Figure 6A-B). These
- 230 data are consistent with reports that tissue resident T cells (T_{RM}) in the lung are relatively short-
- 231 lived compared to other tissues⁴⁴. Furthermore, the majority of AIM⁺ cells did not exhibit a
- 232 CD69⁺CD103⁺ phenotype, suggesting they are unlikely to represent bona fide lung-resident T

233	cells ⁴⁵ (Supplementary Figure 6C). Similarly, we found little evidence for the presence of NL63
234	or CoV-2 cross-reactive MBC in either the LDLN or lung tissues (Supplementary Figure 6D-E).
235	
236	It has been speculated that the dominant CCR6 ⁺ phenotype of CoV-2-specific CD4 T cells may
237	reflect preferential homing of these cells to the lung ³² . ³² We therefore compared the
238	CCR6/CXCR3 phenotypes of hCoV-specific T cells in LDLN to the peripheral blood obtained
239	from the unmatched healthy adult cohort presented in Figures 2-3. After adjustment for baseline
240	activation, we found that LDLN-derived hCoV S-specific Tmem exhibited a predominately
241	CXCR3 ⁺ phenotype, with a substantial population of CCR6 ⁻ CXCR3 ⁺ cells (median 37.7% for
242	HKU1, 37.5% for NL63; Figure 6C-D). In contrast, only 10.8% and 11.2% of circulating HKU1
243	and NL63 S-specific Tmem among the blood donor cohort were CCR6 ⁻ CXCR3 ⁺ (Figure 2D). As
244	we previously observed for cTFH in the periphery, CXCR5 ⁺ hCoV-specific T cells in the LDLN
245	remained more likely to express CCR6 than their Tmem counterparts (Figure 6E-F).
246	Nevertheless, LDLN-derived hCoV-specific CXCR5 ⁺ cells were enriched for CXCR3 expression
247	(median 30.7% CCR6 ⁻ CXCR3 ⁺ for HKU1, 19.4% for NL63) compared to the phenotypes
248	observed among peripheral cTFH (median 6.6% CCR6 ⁻ CXCR3 ⁺ for HKU1, 9.8% for NL63;
249	Figure 6E-F, Figure 3D). Collectively, these data suggest either differential retention or
250	formation of CXCR3 ⁺ hCoV S-specific CD4 T cells in LDLN compared to peripheral blood.

251 Discussion

252 Despite periodic re-infection, most adults experience only mild or asymptomatic hCoV infection, 253 suggesting the presence of at least partially protective immune memory. We find that, in addition 254 to near-universal plasma antibody reactivity to hCoV, memory T cell responses to both α - and 255 βCoV are widespread. In contrast, the relatively modest neutralization activity against NL63 and 256 low frequencies of S-specific MBC suggest that sterilizing humoral immunity is likely absent. 257 Instead, additive contributions of multiple arms of adaptive immunity, in particular anti-viral T 258 cell responses, may underpin protection. While several studies have quantified hCoV-specific T cell responses in adult cohorts^{24,25,27}, it 259 260 was unclear whether the different viruses would elicit phenotypically distinct Tmem or cTFH 261 responses. Together with studies of convalescent SARS-CoV-2-specific T cell responses^{29,32}, our 262 data suggest that the CCR6+ phenotype of circulating hCoV-specific CD4 memory cells may be 263 broadly reflective of coronavirus infection in humans. Indeed, AIM-based assays have 264 consistently identified a high proportion of CCR6⁺CXCR3⁻ cells among SARS-CoV-2 S-specific 265 CD4 T cells^{29,32}, in spite of low IL-17 production following antigen stimulation^{22,29,32}. 266 Interestingly, longitudinal follow-up of COVID-19 convalescent subjects indicated a time-267 dependent increase in the proportion of CCR6+ S-specific cTFH³³, suggesting a convergence of 268 phenotypes between CoV-2-specific and hCoV-specific cTFH memory over time. 269 Chemokine receptor expression on CD4 T cells is often used as a surrogate of cytokine 270 expression and Th1/Th2/Th17 function, but these receptors also regulate lymphocyte trafficking 271 to SLO and tissues. While there was little evidence for hCoV S-specific T cell memory in the 272 lung, both HKU1 and NL63 responses were robustly detected in LDLN. The enrichment of 273 CXCR3⁺ hCoV T cell responses in LDLN compared to peripheral blood suggests a potential

274 involvement of CXCR3 expression in recruitment or retention of these cells out of the 275 circulation. These data are consistent with observations in other respiratory infections, where CXCR3 mediates lung trafficking of antigen-specific CD4 T cells^{46,47}. Future studies will be 276 277 required to address the role, if any, for these cells in contributing to protection from re-exposure 278 to CoV infection. Consistent with other cohorts^{17,19}, we find evidence for CoV-2 cross-reactive CD4 T cells in 279 280 uninfected donors. In vitro expansion of CoV-2 cross-reactive T cell clones has demonstrated the potential for shared specificity with all hCoV^{18,24}. However at a cohort-wide level, we find the 281 282 frequency of CoV-2 cross-reactive cells correlates most strongly with HKU1 memory, although 283 no immediate immunological or demographic features distinguish HKU1-reactive individuals 284 with or without cross-reactive CoV-2 responses. Larger population-based studies will be required 285 to determine any associations between particular HLA class II alleles and cross-reactive CD4 286 responses. Although it has been speculated that pre-existing cross-reactive T cell immunity could be beneficial in the context of SARS-CoV-2 vaccines²³, it should be noted that only CXCR3⁺, 287 288 but not CCR6⁺, cTFH responses appear to correlate with neutralizing antibody titres during COVID-19 convalescence^{29,31,48}. While recall of the CCR6⁺ cTFH could induce expression of 289 290 CXCR3, currently available evidence suggests the highly CCR6-biased responses to hCoV may 291 not be beneficial in the context of vaccination or re-exposure. 292 Overall, these data clarify the characteristics of long-term immunity to endemic coronaviruses, 293 which have comparable magnitudes and share phenotypic features of S-specific antibody and T 294 cell memory across all four hCoV. Insight into the homeostatic maintenance of hCoV immunity 295 is likely to provide a preview of long-term CoV-2-specific immunity established in the 296 population after vaccination or wide-spread infection.

297

298 Methods

299 Subject recruitment and sample collection

300 SARS-CoV-2 uninfected controls were recruited as part of a previous COVID-19 study²⁹, and

301 relevant demographic characteristics are indicated in Figure 1A. For all participants, whole blood

302 was collected with sodium heparin anticoagulant. Plasma was collected and stored at -80°C, and

303 PBMCs were isolated via Ficoll Paque separation, cryopreserved in 10% DMSO/FCS and stored

304 in liquid nitrogen. The study protocols and sample use were approved by the University of Melbourne

305 Human Research Ethics Committee (#2056689) and all associated procedures were carried out in

306 accordance with the approved guidelines. All participants provided written informed consent in

307 accordance with the Declaration of Helsinki.

308 The use of tissue samples from human donors was approved by The University of Melbourne

309 Human Research Ethics Committee (#1954691) and all associated procedures were carried out in

310 accordance with approved guidelines. Tissues were collected from 6 donors: male, age 40-50, brain

death; female, 30-40, brain death; male, 30-40, circulatory death; male, 50-60, brain death; female,

312 60-70, brain death; female, 50-60, brain death. Tissues were passed through 70µM filters and

313 homogenised into single cell suspensions, which were subsequently cryopreserved in 10% DMSO/FCS.

314

315 Expression of coronavirus antigens

A set of trimeric, pre-fusion stabilised coronavirus S proteins (HKU1, 229E, NL63, OC43,

317 SARS-CoV-2) were generated for serological and flow cytometric assays using techniques

318 previously described²⁹. Genes encoding the ectodomain of SARS-CoV-2 S (NC_045512; AA1-

319 1209) with 6 proline stabilisation mutations and furin site removal (Hexapro⁴⁹), the HKU1 S

320 (NC_006577; AA1-1291) and NL63 S (DQ445911.1; AA1-1291) with 2 proline stabilisation

321	mutations	(S-2P).	were cloned	into mammaliar	expression	vectors.	Plasmids	encoding	S-2	P
		· //								

- 322 versions of the ectodomains of OC43 and 229E were kindly provided by Dr Barney Graham,
- 323 NIH. S proteins were expressed in Expi293 or ExpiCHO cells (Thermofisher) using
- 324 manufacturer's instructions and purified using Ni-NTA and size exclusion chromatography.
- 325 Protein integrity was confirmed using SDS-PAGE.
- 326
- 327 ELISA
- 328 Antibody binding to recombinant S proteins was determined by ELISA as previously
- 329 described²⁹. Briefly, 96-well Maxisorp plates (Thermo Fisher) were coated overnight at 4°C with
- 330 2µg/mL recombinant S, blocked with 1% FCS in PBS, and incubated with plasma dilutions for
- two hours at room temperature. Plates were washed, incubated with 1:20,000 dilution of HRP-
- anti-human IgG (Sigma) and developed using TMB substrate (Sigma). Endpoint titres were
- 333 calculated as the reciprocal serum dilution giving signal 2× background using a fitted curve (4
- 334 parameter log regression).
- 335
- 336 Flow cytometric detection of hCoV reactive B cells

Probes for delineating NL63 or SARS-CoV-2 S-specific B cells within cryopreserved human
PBMC were generated by sequential addition of streptavidin-PE (ThermoFisher) or streptavidinBV421 (BD), respectively, to trimeric S protein biotinylated using recombinant Bir-A (Avidity).
Cells were stained with Aqua viability dye (ThermoFisher). PBMC, lung and lymph node cells
were surface stained with the following monoclonal antibodies: CD14-BV510 (M5E2), CD3BV510 (OKT3), CD8a-BV510 (3GA), CD16-BV510 (3G8), CD10-BV510 (HI10a), SA-BV510
(BD), IgG-BV786 (G18-145), IgD-Cy7PE (IA6-2), and CD19 ECD (J3-119) (Beckman). Cells

were washed, fixed with 1% formaldehyde and acquired on a BD LSR Fortessa using BD FACSDiva.

346

347 Flow cytometric detection of antigen-specific CD4 T cells

348 Cryopreserved human PBMC were thawed and rested for four hours at 37°C. Cells were cultured 349 in 96-well plates at 1-2x10⁶ cells/well and stimulated for 20 hours with 2µg/mL of recombinant S 350 protein from HKU1, NL63, 229E, OC43 or SARS-CoV-2. Selected donors were also stimulated 351 with SEB (1µg/mL) as a positive control. Following stimulation, cells were washed, stained 352 with Live/dead Blue viability dye (ThermoFisher), and a cocktail of monoclonal antibodies. 353 PBMC were surface stained with the following monoclonal antibodies: CD3 BUV395 354 (SK7), CD45RA PeCy7 (HI100), CD20 BUV805 (2H7), CD154 APC Cy-7 (TRAP-1), CCR7 355 Alexa Fluor 700 (150503) (BD Biosciences), CD27 BV510 (M-T271), CD4 BV605 (RPA-356 T4), CD8 BV650 (RPA-T8), CD25 APC (BC96), OX-40 PerCP-Cy5.5 (ACT35), CD69 FITC (FN50), CD137 BV421 (4B4-1), CXCR3 PE Dazzle (G025H7), CCR6 BV786 357 358 (G034E3) (Biolegend), and CXCR5 PE (MU5UBEE, ThermoFisher). Monoclonal antibody 359 staining for lung and lymph node cells included: CD45RA PeCy7 (HI100), CD20 360 BUV805 (2H7), CD154 APC Cy-7 (TRAP-1), EpCam BV711 (EBA-1), CD103 BUV395 (Ber-361 ACT8) (BD Biosciences), CD3 BV510 (SK7), CD4 BV605 (RPA-T4), CD8 BV650 (RPA-362 APC (BC96), OX-40 PerCP-Cv5.5 (ACT35), CD69 T8), CD25 FITC (FN50), PD-1 BV421 (EH12.217), CXCR3 PE Dazzle (G025H7), CCR6 BV786 (G034E3) (Biolegend), and 363 364 CXCR5 PE (MU5UBEE, ThermoFisher) Cells were washed, fixed with 1% formaldehyde and 365 acquired on a BD LSR Fortessa using BD FACS Diva.

367 *NL63 pseudovirus neutralisation assay*

368 HIV-based lentivirus particles pseudotyped with S from NL63 were generated based on a previously published protocol⁵⁰. Lenti-X 293T cells (TakaraBio) were co-transfected with a 369 370 lentiviral backbone plasmid expressing Luciferase-IRES-ZsGreen (BEI Resources; NR-52948), 371 helper plasmids encoding HIV Tat, Gag-Pol and Rev (BEI Resources; NR-52948) and a 372 pseudotyping plasmid encoding native NL63 S protein (DQ445911.1). Lenti-X 293T cells were seeded in T175 flasks (18×10⁶ cells/flask) and transfected using lipofectamine (ThermoFisher 373 374 Scientific) according to manufacturer's instructions. At 6 hours after transfection, cell culture 375 media was replaced with 36ml of fresh D10 media (DMEM with 10% FCS and 1% PSG). After 376 another 48 hours of incubation, cell culture supernatants containing virions were clarified via 377 centrifugation at 500g for 10 min, filtered through a 0.45µM PES filter and stored at -80°C. 378 Infectivity of virions was determined by titration on 293T-ACE2 cells (BEI resources; NR-52511).

379

380 For the NL63 pseudovirus neutralisation assay, poly-L-lysine (Sigma Aldrich) coated 96-well 381 white plates (Interpath) were seeded with 293T-ACE2 cells (12,000 cells per well in 60µl). The 382 next day, eight 2-fold serial dilutions of plasma (60µl) were incubated with NL63 pseudovirus 383 (60µl) for 1 hour at 37°C (final plasma dilution of 1:20-1:2,560). Plasma-pseudovirus mixtures 384 (100µl) were then added to 293T-ACE2 cells and incubated at 37°C for 48 hours. Plasma samples 385 were tested in triplicate, with "virus+cells" and "virus only" controls included to represent 100% 386 and 0% infectivity respectively. After 48 hours, all cell culture media was carefully removed from 387 wells. Cells were lysed with 25µl of passive lysis buffer (Promega), incubated on an orbital shaker 388 for 15 mins and developed with 30µl britelite plus luciferase reagent (Perkin Elmer). 389 Luminescence was read using a FLUOstar Omega microplate reader (BMG Labtech). The relative 390 light units (RLU) measured were used to calculate %neutralisation with the following formula:

391 ('Virus+cells' – 'sample') \div ('Virus+cells' – 'Virus only') \times 100. The half maximal inhibitory 392 concentration for plasma (IC₅₀) was determined using four-parameter nonlinear regression in 393 GraphPad Prism with curve fits constrained to have a minimum of 0% and maximum of 100% 394 neutralisation.

395

396 Statistics

397 Statistical analysis was performed in GraphPad Prism v9. All T cell stimulation data is presented

398 after background subtraction using the unstimulated control. Two group comparisons were

399 performed using the Mann-Whitney test, or the Wilcoxon test for paired data. Correlations were

400 performed using the Spearman test. P values were considered significant if < 0.05.

401

402 Acknowledgements

403 The authors would like to thank the study participants and clinical teams for their participation in 404 and assistance with the study. We gratefully acknowledge the generosity of the organ donor 405 families for providing valuable tissue samples. We acknowledge the Melbourne Cytometry 406 Program for provision of flow cytometry services. Funding for this work was provided by the 407 Victorian Government, a Doherty Collaborative Research Award (JJ), the ARC Centre of 408 Excellence in Convergent Bio-Nano Science and Technology (SJK), an NHMRC program grant 409 APP1149990 (SJK), and philanthropic support from the Paul Ramsay Foundation (SJK and 410 AKW). AKW is funded by an NHMRC Investigator grant. JAJ and SJK are funded by NHMRC 411 fellowships.

412

414 Author Contributions

- 415 HXT, WSL, AKW, SJK and JAJ designed the study, analysed the results and wrote the
- 416 manuscript. KMW, HXT, CN, WSL, RE, HGK, TA, AKW and JAJ performed the experiments.
- 417 RJ, GS, BZW, OY, TT, MLG, HO, RD, AV, LKM, CLG facilitated collection of human tissues.
- 418 All authors read, edited, and approved the manuscript.
- 419
- 420 Figure Legends

421 Figure 1. hCoV and CoV-2 CD4 Tmem responses among healthy subjects.

- 422 (A) Ages of the CoV-2 uninfected adult cohort participants (n=21 female, n=21 male) (B)
- 423 Plasma samples were screened by ELISA for reactivity against S proteins from hCoV or CoV-2
- 424 (n=42). Data are presented as the reciprocal endpoint titre. Dashed line indicates the limit of
- 425 detection of the assay. (C) Representative plots of coronavirus S-specific CD4 Tmem
- 426 (CD3⁺CD4⁺CXCR5⁻CD45RA⁻) from a single individual measured by OX-40 and CD25
- 427 expression (control well stimulated with BSA). (D) Number of individuals with S-specific
- 428 responses greater than 0.01% of total Tmem for each indicated antigen (n=42). Numbers in bars
- 429 indicate the percentage of responders for each antigen. (E) Frequency of S-specific Tmem for
- 430 each antigen (n=42). Lines indicate median. Values represent background subtracted responses;
- 431 frequencies below 0.01% after background subtraction were assigned a value of 0.01%.
- 432

433 Figure 2. Memory and Th phenotype of hCoV and cross-reactive SARS-CoV-2 CD4 Tmem

- 434 **responses.** (A) Representative staining of CD27 and CCR7 on the total Tmem population (black)
- 435 or HKU1 S-specific Tmem (red) in a single donor. (B) Quantification of memory phenotype
- 436 among bulk Tmem (n=42), HKU1 (n=36), OC43 (n=34), 229E (n=27), NL63 (n=21) or CoV-2

(n=20)-specific Tmem. (C) Representative staining of CCR6 and CXCR3 on the total Tmem

438 population (black) or HKU1 S-specific Tmem (red) in a single donor. (D) Quantification of Th 439 phenotype among bulk Tmem (n=42), HKU1 (n=36), OC43 (n=34), 229E (n=27), NL63 (n=21) 440 or CoV-2 (n=20)-specific Tmem. (E) Comparison of hCoV and SARS-CoV-2-specific T cell 441 phenotype in a single donor with responses to all antigens. In all graphs, individuals were 442 excluded if they did not exhibit a response to a particular antigen. 443 444 Figure 3. Memory and Th phenotype of hCoV and cross-reactive CoV-2 cTFH responses. 445 (A) Frequency of S-specific cTFH for each antigen (n=42). Lines indicate median. Values 446 represent background subtracted responses; frequencies below 0.01% after background 447 subtraction were assigned a value of 0.01%. Data points are segregated and coded as individuals 448 without (closed circles, n=24) or with (open circles, n=18) CoV-2 cross-reactive responses. (B) 449 Comparison of HKU1 S-specific T cell frequencies in Tmem or cTFH subsets. Plots indicate 450 representative data from one donor. Graph shows compilation of responses from all donors 451 (n=42). (C) Representative staining of CCR6 and CXCR3 on the total cTFH population (black), 452 HKU1-specific (red) or CoV-2-specific cTFH (teal) in a single donor. (D) Quantification of Th 453 phenotype among bulk cTFH (n=42), HKU1 (n=36), OC-43 (n=34), 229E (n=27), NL63 (n=21) 454 or SARS-CoV-2 (n=20)-specific Tmem. (E) Representative CCR6/CXCR3 expression on bulk 455 (black) or HKU1 S-specific (red) Tmem and cTFH. (F) Paired comparison of the frequency of 456 CCR6⁺CXCR3⁻ cells among hCoV or CoV-2 S-specific Tmem and cTFH populations among 457 responding subjects. HKU, n=34; OC43, n=34; 229E, n=21; NL63, n=18; CoV-2, n=13. 458 Statistics assessed by Wilcoxon test. ***p<0.001, **p<0.01, *p<0.05

459

460 Figure 4. Correlation between HKU1 and CoV-2 cross-reactive Tmem responses.

461 (A) Frequency of S-specific Tmem for each antigen (n=42). Lines indicate median. Values 462 represent background subtracted responses; frequencies below 0.01% after background 463 subtraction were assigned a value of 0.01%. Data points are segregated and coded as individuals 464 without (closed circles, n=22) or with (open circles, n=20) CoV-2 cross-reactive responses. (B) 465 Spearman correlation between the frequency of CoV-2 and hCoV S-specific Tmem (n=42, black 466 text). Correlation p value among individuals with CoV-2 responses >0.01% (n=20, grey dots) is 467 shown in grey text. (C) Representative staining of two healthy donors with S-specific responses 468 to all four hCoV antigens but differential responses to CoV-2 S. 469 470 Figure 5. Relationship between serologic, T cell and B cell hCoV memory. (A) Spearman 471 correlation between HKU1 or NL63 S-specific IgG and the frequency of antigen-specific Tmem 472 or cTFH (n=42). Representative staining of IgD- B cells with NL63 or CoV-2 probes and 473 quanification of NL63 and CoV-2 S-specific MBC (n=18). (C) Spearman correlation of NL63 S-474 specific MBC and plasma binding IgG titres (n=18). MBC frequency was assigned a minimum 475 value of 0.001%. (D) Spearman correlation between plasma NL63 neutralization activity and 476 NL63 S-specific IgG titres or MBC (n=12). (E) Spearman correlation between NL63 477 neutralization activity and either total NL63 S-specific cTFH or the frequency of CCR6+ 478 antigen-specific cTFH. 479

480 Figure 6. CD4 T cell hCoV memory in human lung draining lymph nodes (A)

481 Representative staining of AIM and CD154 expression following stimulation with HKU1, NL63

482 or CoV-2 S among lung-draining lymph node cell suspensions. (B) Frequency of hCoV or cross-

- 483 reactive CoV-2 responses among Tmem or CD4⁺CXCR5⁺ populations (n=5). (C-E)
- 484 Representative staining (C, E) and quantification (D, F) of CCR6 and CXCR3 expression on
- 485 Tmem (C, D) or CXCR5⁺ (E, F) S-specific cells (n=5).

487	Refer	ences
488		
489	1	Liu, D. X., Liang, J. Q. & Fung, T. S. Human Coronavirus-229E, -OC43, -NL63, and -HKU1.
490		Reference Module in Life Sciences, B978-970-912-809633-809638.821501-X, doi:10.1016/B978-
491		0-12-809633-8.21501-X (2020).
492	2	Dijkman, R. et al. The dominance of human coronavirus OC43 and NL63 infections in infants. J
493		<i>Clin Virol</i> 53 , 135-139, doi:10.1016/j.jcv.2011.11.011 (2012).
494	3	Dijkman, R. et al. Human coronavirus NL63 and 229E seroconversion in children. J Clin
495		Microbiol 46, 2368-2373, doi:10.1128/jcm.00533-08 (2008).
496	4	Zhou, W., Wang, W., Wang, H., Lu, R. & Tan, W. First infection by all four non-severe acute
497		respiratory syndrome human coronaviruses takes place during childhood. BMC infectious
498		diseases 13, 433, doi:10.1186/1471-2334-13-433 (2013).
499	5	Severance, E. G. <i>et al.</i> Development of a nucleocapsid-based human coronavirus immunoassay
500	-	and estimates of individuals exposed to coronavirus in a U.S. metropolitan population. <i>Clin</i>
501		<i>Vaccine Immunol</i> 15 , 1805-1810, doi:10.1128/cvi.00124-08 (2008).
502	6	Edridge A. W. D. et al. Seasonal coronavirus protective immunity is short-lasting. <i>Nature</i>
503	Ũ	<i>medicine</i> doi:10.1038/s41591-020-1083-1 (2020)
504	7	Galanti, M. & Shaman, I. Direct Observation of Repeated Infections With Endemic
505	,	Coronaviruses The Journal of infectious diseases doi:10.1093/infdis/ijaa392 (2020)
506	8	Callow K A Parry H F Sergeant M & Tyrrell D A The time course of the immune
507	0	response to experimental coronavirus infection of man <i>Enidemial Infect</i> 105 435-446
508		Agi:10 1017/s0050268800048010 (1000)
500	9	Leniller Ω at all High incidence but low burden of coronaviruses and preferential associations
510)	between respiratory viruses I Clin Microbiol 51 , 3030, 3046, doi:10.1128/jcm.01078, 13 (2013)
511	10	Gerna G et al Genetic variability of human coronavirus OC43- 229E- and NI 63-like strains
512	10	and their association with lower respiratory tract infections of hospitalized infants and
512		immunocompromised patients. <i>Journal of medical virology</i> 78 , 938, 949, doi:10.1002/imy.20645
517		(2006)
515	11	(2000). Pene E at al Coronavirus 220E related nneumonia in immunocompromised nationts. <i>Clinical</i>
516	11	infactions diseases : an official publication of the Infactions Diseases Society of America 37 , 020
517		1) and a second straight of the injectious Diseases Society of America 5 7, 929-
518	12	McMahan V at al Correlates of protection against SADS CoV 2 in rhous macaques. Nature
510	12	Methanan, K. <i>et al.</i> Correlates of protection against SAKS-Cov-2 in mesus macaques. <i>Nature</i> , d_{2} :10 1028/c41586 020 02041 6 (2020)
520	12	doi.10.1056/841560-020-05041-0 (2020). Les W.S. et al. Desey of Fe dependent entitledy functions after mild to moderate COVID 10
520	15	Lee, w. S. <i>et al.</i> Decay of FC-dependent antibody functions after finite to moderate $CO \times ID$ -19. mod D_{viv} , 2020 2012 2012 20248142, d_{viv} to 1101/2020 12 12 20248142 (2020)
521	14	mearXiV, 2020.2012.2015.20248145, doi:10.1101/2020.12.15.20248145 (2020).
522	14	Serva, K. J. <i>et al.</i> Distinct systems serology features in children, elderly and COVID patients. $m_{ed}D_{min}$ 2020 2005 2011 20008450. A_{ei} 10 1101/2020 05 11 20008450 (2020)
525 524	15	mearxiv, 2020.2005.2011.20098459, doi:10.1101/2020.05.11.20098459 (2020).
524	13	Ng, K. w. <i>et al.</i> Preexisting and de novo numoral infinunity to SARS-Cov-2 in numans. <i>Science</i>
525	16	(<i>New York</i> , N.Y.), doi:10.1126/science.abe1107 (2020).
520	10	Song, G. <i>et al.</i> Cross-reactive serum and memory B cell responses to spike protein in SARS-
527		CoV-2 and endemic coronavirus infection. <i>bioRxiv</i> , 2020.2009.2022.308965,
528	17	doi:10.1101/2020.09.22.308965 (2020).
529	Γ7	Braun, J. <i>et al.</i> SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.
530	10	<i>Nature</i> , doi:10.1038/s41586-020-2598-9 (2020).
531	18	Mateus, J. <i>et al.</i> Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.
532	10	<i>Science (New York, N.Y.)</i> 370 , 89-94, doi:10.1126/science.abd3871 (2020).
533	19	Gritoni, A. <i>et al.</i> Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with
534	•	COVID-19 Disease and Unexposed Individuals. <i>Cell</i> , doi:10.1016/j.cell.2020.05.015 (2020).
535	20	Annıka, N. et al. SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-
536		cell recognition. <i>Research Square</i> , doi:10.21203/rs.3.rs-35331/v1 (2020).

537 538	21	Ogbe, A. <i>et al.</i> T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>medRxiv</i> , 2020.2009.2028.20202929,
539		doi:10.1101/2020.09.28.20202929 (2020).
540	22	Sekine, T. et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild
541		COVID-19. <i>Cell</i> 183 , 158-168.e114, doi:10.1016/j.cell.2020.08.017 (2020).
542	23	Sette, A. & Crotty, S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. <i>Nature</i>
543		reviews. Immunology 20 , 457-458, doi:10.1038/s41577-020-0389-z (2020).
544	24	Woldemeskel, B. A. et al. Healthy donor T cell responses to common cold coronaviruses and
545		SARS-CoV-2. The Journal of clinical investigation, doi:10.1172/jci143120 (2020).
546	25	Bacher, P. et al. Low avidity CD4+ T cell responses to SARS-CoV-2 in unexposed individuals
547		and humans with severe COVID-19. Immunity, doi:10.1016/j.immuni.2020.11.016 (2020).
548	26	Sagar, M. et al. Recent endemic coronavirus infection is associated with less severe COVID-19.
549		The Journal of clinical investigation, doi:10.1172/jci143380 (2020).
550	27	Mok, C. K. P. et al. T-cell responses to MERS coronavirus infection in people with occupational
551		exposure to dromedary camels in Nigeria: an observational cohort study. The Lancet. Infectious
552		diseases, doi:10.1016/s1473-3099(20)30599-5 (2020).
553	28	Stolley, J. M. et al. Retrograde migration supplies resident memory T cells to lung-draining LN
554		after influenza infection. The Journal of experimental medicine 217, doi:10.1084/jem.20192197
555		(2020).
556	29	Juno, J. A. <i>et al.</i> Immunogenic profile of SARS-CoV-2 spike in individuals recovered from
557		COVID-19. medRxiv, 2020.2005.2017.20104869, doi:10.1101/2020.05.17.20104869 (2020).
558	30	Dan, J. M. et al. A Cytokine-Independent Approach To Identify Antigen-Specific Human
559		Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood.
560		Journal of immunology (Baltimore, Md. : 1950) 197 , 983-993, doi:10.4049/iimmunol.1600318
561		(2016).
562	31	Zhang, J. <i>et al.</i> Spike-specific circulating T follicular helper cell and cross-neutralizing antibody
563	01	responses in COVID-19-convalescent individuals. <i>Nature microbiology</i> . doi:10.1038/s41564-
564		020-00824-5 (2020)
565	32	Rydyznski Moderbacher, C. <i>et al.</i> Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute
566	02	COVID-19 and Associations with Age and Disease Severity. <i>Cell</i> . doi:10.1016/j.cell.2020.09.038
567		(2020).
568	33	Dan I M <i>et al</i> Immunological memory to SARS-CoV-2 assessed for greater than six months
569	55	after infection <i>bioRxiv</i> 2020 2011 2015 383323 doi:10.1101/2020.11.15.383323 (2020)
570	34	Brenna E <i>et al</i> CD4(+) T Follicular Helner Cells in Human Tonsils and Blood Are Clonally
571	51	Convergent but Divergent from Non-Tfh CD4(+) Cells <i>Cell reports</i> 30 137-152 e135
572		doi:10.1016/i celrep 2019.12.016 (2020)
573	35	Bentehibel S F <i>et al</i> Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody
574	55	responses to influenza vaccination. Science translational medicine 5, 176ra132
575		doi:10.1126/scitranslmed 3005191 (2013)
576	36	Crotty S T Follicular Helper Cell Biology: A Decade of Discovery and Diseases Immunity 50
577	50	1132-1148 doi:10.1016/j.immuni 2019.04.011 (2019)
578	37	Koutsakos M. Nauven T. H. O. & Kedzierska K. With a Little Help from T. Follicular Helper
579	51	Friends: Humoral Immunity to Influenza Vaccination Journal of immunology (Raltimora Md
580		1050 202 260 267 doi:10.000/jimmunol.1800086 (2010)
581	28	1950 202, 500-507, doi:10.4049/jimmunoi.1000900 (2019).
587	50	functional and correlate with broadly neutralizing HIV antibady responses. <i>Immunity</i> 20, 759
582		760. doi:10.1016/j.jmmuni.2013.08.031 (2013)
587	30	107, $401.10.1010/J.IIIIIIIIII.2013.00.031 (2013).Linterman M A & Hill D I. Can follicular helper T calls be targeted to improve veccine.$
585	59	efficacy? F1000Research 5 doi:10.12688/f1000research 7298.1 (2016)
505		cincacy: 1/1000/(esearch 3, 001.10.12000/11000/esearch./300.1 (2010).

586 587	40	Vella, L. A. <i>et al.</i> T follicular helper cells in human efferent lymph retain lymphoid characteristics. <i>The Journal of clinical investigation</i> 129 , 3185-3200, doi:10.1172/jci125628
388		(2019).
589	41	Morita, R. <i>et al.</i> Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and
590		contain specific subsets that differentially support antibody secretion. <i>Immunity</i> 34 , 108-121,
591		doi:10.1016/j.immuni.2010.12.012 (2011).
592	42	Jaimes, J. A., André, N. M., Chappie, J. S., Millet, J. K. & Whittaker, G. R. Phylogenetic
593		Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary
594		Distinct and Proteolytically Sensitive Activation Loop. J Mol Biol 432, 3309-3325,
595		doi:10.1016/j.jmb.2020.04.009 (2020).
596	43	Anthony, S. M. et al. Lung-draining lymph-node-resident memory CD8 T cells mediate local
597		protective immunity. The Journal of Immunology 202, 198.197-198.197 (2019).
598	44	Slütter, B. et al. Dynamics of influenza-induced lung-resident memory T cells underlie waning
599		heterosubtypic immunity. Science immunology 2, doi:10.1126/sciimmunol.aag2031 (2017).
600	45	Oja, A. E. et al. Trigger-happy resident memory CD4(+) T cells inhabit the human lungs.
601		Mucosal immunology 11, 654-667, doi:10.1038/mi.2017.94 (2018).
602	46	Jeyanathan, M. et al. CXCR3 Signaling Is Required for Restricted Homing of Parenteral
603		Tuberculosis Vaccine-Induced T Cells to Both the Lung Parenchyma and Airway. Journal of
604		immunology (Baltimore, Md. : 1950) 199, 2555-2569, doi:10.4049/jimmunol.1700382 (2017).
605	47	Kohlmeier, J. E. et al. CXCR3 directs antigen-specific effector CD4+ T cell migration to the lung
606		during parainfluenza virus infection. Journal of immunology (Baltimore, Md. : 1950) 183, 4378-
607		4384, doi:10.4049/jimmunol.0902022 (2009).
608	48	Gong, F. et al. Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent
609		individuals. The Journal of clinical investigation, doi:10.1172/jci141054 (2020).
610	49	Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science
611		(New York, N.Y.) 369, 1501-1505, doi:10.1126/science.abd0826 (2020).
612	50	Crawford, K. H. D. et al. Protocol and Reagents for Pseudotyping Lentiviral Particles with
613		SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses 12, doi:10.3390/v12050513
614		(2020).
615		

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC-ND 4.0 International license.



Figure 1. hCoV and CoV-2 CD4 Tmem responses among healthy subjects.

(A) Ages of the CoV-2 uninfected adult cohort participants (n=21 female, n=21 male) (B) Plasma samples were screened by ELISA for reactivity against S proteins from hCoV or CoV-2 (n=42). Data are presented as the reciprocal endpoint titre. Dashed line indicates the limit of detection of the assay. (C) Representative plots of coronavirus S-specific CD4 Tmem (CD3⁺CD4⁺CXCR5⁻CD45RA⁻) from a single individual measured by OX-40 and CD25 expression (control well stimulated with BSA). (D) Number of individuals with S-specific responses greater than 0.01% of total Tmem for each indicated antigen (n=42). Numbers in bars indicate the percentage of responders for each antigen. (E) Frequency of S-specific Tmem for each antigen (n=42). Lines indicate median. Values represent background subtracted responses; frequencies below 0.01% after background subtraction were assigned a value of 0.01%.



Figure 2. Memory and Th phenotype of hCoV and cross-reactive SARS-CoV-2 CD4 Tmem responses. (A) Representative staining of CD27 and CCR7 on the total Tmem population (black) or HKU1 S-specific Tmem (red) in a single donor. (B) Quantification of memory phenotype among bulk Tmem (n=42), HKU1 (n=36), OC43 (n=34), 229E (n=27), NL63 (n=21) or CoV-2 (n=20)-specific Tmem. (C) Representative staining of CCR6 and CXCR3 on the total Tmem population (black) or HKU1 S-specific Tmem (red) in a single donor. (D) Quantification of Th phenotype among bulk Tmem (n=42), HKU1 (n=36), OC43 (n=34), 229E (n=27), NL63 (n=21) or CoV-2 (n=20)-specific Tmem. (E) Comparison of hCoV and SARS-CoV-2-specific T cell phenotype in a single donor with responses to all antigens. In all graphs, individuals were excluded if they did not exhibit a response to a particular antigen.



Figure 3. Memory and Th phenotype of hCoV and cross-reactive CoV-2 cTFH responses. (A) Frequency of S-specific cTFH for each antigen (n=42). Lines indicate median. Values represent background subtracted responses; frequencies below 0.01% after background subtraction were assigned a value of 0.01%. Data points are segregated and coded as individuals without (closed circles, n=24) or with (open circles, n=18) CoV-2 cross-reactive responses. (B) Comparison of HKU1 S-specific T cell frequencies in Tmem or cTFH subsets. Plots indicate representative data from one donor. Graph shows compilation of responses from all donors (n=42). (C) Representative staining of CCR6 and CXCR3 on the total cTFH population (black), HKU1-specific (red) or CoV-2-specific cTFH (teal) in a single donor. (D) Quantification of Th phenotype among bulk cTFH (n=42), HKU1 (n=36), OC-43 (n=34), 229E (n=27), NL63 (n=21) or SARS-CoV-2 (n=20)-specific Tmem. (E) Representative CCR6/CXCR3 expression on bulk (black) or HKU1 S-specific (red) Tmem and cTFH. (F) Paired comparison of the frequency of CCR6⁺CXCR3⁻ cells among hCoV or CoV-2 S-specific Tmem and cTFH populations among responding subjects. HKU, n=34; OC43, n=34; 229E, n=21; NL63, n=18; CoV-2, n=13. Statistics assessed by Wilcoxon test. ***p<0.001, **p<0.01, *p<0.05



Figure 4. Correlation between HKU1 and CoV-2 cross-reactive Tmem responses. (A) Frequency of S-specific Tmem for each antigen (n=42). Lines indicate median. Values represent background subtracted responses; frequencies below 0.01% after background subtraction were assigned a value of 0.01%. Data points are segregated and coded as individuals without (closed circles, n=22) or with (open circles, n=20) CoV-2 cross-reactive responses. (B) Spearman correlation between the frequency of CoV-2 and hCoV S-specific Tmem (n=42, black text). Correlation p value among individuals with CoV-2 responses >0.01% (n=20, grey dots) is shown in grey text. (C) Representative staining of two healthy donors with S-specific responses to all four hCoV antigens but differential responses to CoV-2 S.



Α

Figure 5. Relationship between serologic, T cell and B cell hCoV memory. (A)

Spearman correlation between HKU1 or NL63 S-specific IgG and the frequency of antigenspecific Tmem or cTFH (n=42). Representative staining of IgD- B cells with NL63 or CoV-2 probes and quanification of NL63 and CoV-2 S-specific MBC (n=18). (C) Spearman correlation of NL63 S-specific MBC and plasma binding IgG titres (n=18). MBC frequency was assigned a minimum value of 0.001%. (D) Spearman correlation between plasma NL63 neutralization activity and NL63 S-specific IgG titres or MBC (n=12). (E) Spearman correlation between NL63 neutralization activity and either total NL63 S-specific cTFH or the frequency of CCR6+ antigen-specific cTFH.



Figure 6. CD4 T cell hCoV memory in human lung draining lymph nodes (A) Representative staining of AIM and CD154 expression following stimulation with HKU1, NL63 or CoV-2 S among lung-draining lymph node cell suspensions. (B) Frequency of hCoV or cross-reactive CoV-2 responses among Tmem or CD4⁺CXCR5⁺ populations (n=5). (C-E) Representative staining (C, E) and quantification (D, F) of CCR6 and CXCR3 expression on Tmem (C, D) or CXCR5⁺ (E, F) S-specific cells (n=5).

Supplementary Figures



Supplementary Figure 1. CD4 T cell gating strategy. (A) Lymphocytes were identified by forward and side scatter, followed by doublet exclusion (FSC-A vs FSC-H), and gating on live cells with a consistent fluorescence profile over time. T cells were identified as CD20-CD3+, and CD4+CD8- cells were further defined as cTFH (CXCR5+CD45RA-) or Tmem (CXCR5-CD45RA-). (B) Tmem and cTFH populations were phenotyped using memory markers (CD27 vs CCR7) or chemokine receptors (CCR6 vs CXCR3).



Supplementary Figure 2. CD4 Tmem responses measured by different AIM

combinations. (A) Comparison of AIM marker readouts (OX-40+CD25+ vs OX-40+CD137+) in a single individual for S-specific responses to all four hCoV antigens and SARS-CoV-2 S. (B) Frequency of S-specific Tmem for each antigen (n=42). Bars indicate median. Values represent background subtracted responses; frequencies below 0.01% after background subtraction were assigned a value of 0.01%. Symbols and colours indicate individual donors with SARS-CoV-2 responses >0.01% and are matched to the individuals coded in Figure 2C. (C) Comparison of SARS-CoV-2-specific Tmem CCR6 and CXCR3 phenotype based on identification by OX-40⁺CD25⁺ or OX-40⁺CD137⁺ gates.



Supplementary Figure 3. Demographic and immunological characteristics of total hCoV and CoV-2 cross-reactive responses. (A) Spearman correlation of age and total hCoV Tmem frequency (n=42). (B) Total hCoV frequency according to gender (n=42). (C) Age and (D) gender distribution among individuals with no (<0.01%) CoV-2 S-specific CD4 Tmem responses (n=22) or with CoV-2 responses (n=20). (E) Phenotype of HKU1-specific Tmem in individuals without (black, n=17) or with (grey, n=19) cross-reactive CoV-2 responses. Lines and error bars indicate median and interquartile range.



Supplementary Figure 4. Gating strategy for resolving antigen-specific B cells Lymphocytes were identified by FSC-A vs SSC-A gating, followed by doublet exclusion (FSC-A vs FSC-H), and gating on live CD19+ B cells. Class-switched B cells were identified as IgD-, IgG+. Binding to SARS-CoV-2 or NL63 spike was assessed.



Supplementary Figure 5. Lymph node and lung CD4 T cell gating strategy. (A) CD4 T cells in lymph node or lung samples were identified as lymphocytes (identified by forward and side scatter, followed by doublet exclusion) with a CD20-EpCam-Live/Dead-CD3+CD8-CD4+ phenotype. (B) Memory CD4 T cell subsets in lung draining lymph nodes were identified as CD45RA-, followed by gating based on PD-1 and CXCR5 expression to identify TFH, pre-TFH and Tmem subsets. (C) In lung samples, memory CD4 T cells were identified as CD45RA-. T_{RM} cells were identified as CD69+CD103+.



Supplementary Figure 6. hCoV and CoV-2 T cell and B cell responses in LDLN and lung. (A) Representative responses to HKU1, NL63 or CoV-2 S antigen stimulation among CD4⁺CD45RA⁻ T cells in the lung. (B) Quantification of S-specific T cell responses (n=6 for NL63 and CoV-2, n=5 for HKU1). (C) Expression of CD69 and CD103 on total CD4⁺CD45RA⁻ lung T cells (grey) versus HKU S-specific T cells (red). (D) Representative staining of NL63 and CoV-2 S-specific MBC in LDLN and lung samples. (E) Quantification of S-specific MBC among PBMC samples from the healthy adult cohort (n=18), or human tissue biobank LDLN (n=6) or lung (n=6).